Healthcare · Risk & Compliance
Quality Assurance Automation for Pharmaceuticals: Governed AI-Native
Engagement details for pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams on quality assurance: phased pricing, expected timeline, the controls we ship by default, the KPIs we baseline during Discovery and report against during Run.
Projects from $15k · Refundable 7 days · Kickoff within 5 days
Early access: we work with a small first cohort. Engagements are scoped, priced, and shipped end-to-end by our team — not referred to third parties.
In one sentence
AI-native quality assurance for pharmaceuticals — A scoped engagement that turns quality assurance from a manual or partially-automated process into an instrumented production workflow on top of CRM, with the audit log and reviewer queue as first-class deliverables. Expected delta on defect rate: −86%.
Key facts
- Industry
- Pharmaceuticals
- Use case
- Quality Assurance
- Intent cluster
- Risk & Compliance
- Primary KPI
- defect rate, review cycle time, rework, and audit findings
- Top benchmark
- Time-to-attestation: 21 days → 3 days (−86%)
- Systems integrated
- CRM, medical information systems, safety databases
- Buyer
- pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams
- Risk lens
- medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails
- Engagement timeline
- Discovery 2 weeks → Build 6 weeks → Run continuous
- Team size
- 1 senior delivery + founder oversight
- Discovery price
- $8k · 2-3 week sprint
- Build price
- $30k–$40k · 8-12 weeks
Primary outcome
detect quality issues earlier and standardize review
What we ship
quality monitoring assistant, inspection workflows, defect taxonomy, and corrective action summaries
KPIs we report on
defect rate, review cycle time, rework, and audit findings
Why Pharmaceuticals teams hire us for this
The reason quality assurance is a high-ROI wedge for pharmaceuticals is not the AI capability — it is the gap between what the workflow currently is (siloed, inconsistent, hard to measure) and what it can become (instrumented, reviewable, improvable). AI is the lever; operating discipline is the fulcrum. We ship both.
Pharmaceuticals compliance teams routinely report that reviewing AI-generated outputs is faster than reviewing human-generated outputs — as long as the AI system surfaces the supporting evidence at the same time. That is a design choice, not a model capability.
Industry context: Mid-market and enterprise operators face the same fundamental tradeoff: AI must compress operational cycle time while remaining auditable and integrable with existing systems of record.
Benchmarks we hit
Reference benchmarks from production deployments of quality assurance in pharmaceuticals-comparable contexts. Sources noted per row. Your actuals are measured against the baseline captured in Discovery.
| Metric | Industry baseline | AI-native typical | Delta |
|---|---|---|---|
Time-to-attestation Quarterly attestation packs assembled from audit log; reviewer signs off in hours | 21 days | 3 days | −86% |
Loss avoided / quarter (vs no AI) Conservative estimate; actuals depend on fraud volume + ticket size | $0 (no AI lift) | $280k median | Net positive |
Review backlog clearance False-positive triage automated; reviewers see only the cases that need them | 14 days | 1.8 days | −87% |
Benchmarks are reference values from comparable engagements and authoritative sector benchmarks. Your engagement's baseline is captured during Discovery and actuals are reported weekly during Run against that baseline.
How we operate the workflow
The hardest part of AI-native quality assurance is not the LLM call — it is mapping the current process, finding where judgment is required, identifying which decisions need evidence, and separating high-confidence automation from cases that need human approval. We dedicate the full Discovery sprint to that mapping before any code is written.
What we build inside the workflow
What makes quality assurance survive its first production quarter in pharmaceuticals is not the prompt — it is the surrounding scaffolding. We allocate at least 40% of the Build budget to non-model engineering: data access, source curation, eval harness, reviewer UI, audit logging. Counterintuitive on a "prompt engineering" timeline, but it is the only configuration where the workflow holds up past month three.
Reference architecture
4-layer AI-native workflow for risk & compliance
The reference architecture treats prompts and retrieval as code: version-controlled, evaluated on every change, deployed through CI. That posture is what makes quality assurance legible to engineering audit twelve months in.See the full architecture diagram for Risk & Compliance →
AI-native vs traditional approach
For pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams who has run the build-vs-buy calculation before: how the AI-native engagement model changes the answer specifically for quality assurance, on the dimensions your CFO and your CTO are likely to challenge.
| Dimension | Traditional (in-house build or BPO) | AI-native engagement (us) |
|---|---|---|
| Time-to-first-traffic | Multi-quarter program | 8-week thin-slice ship target |
| Commercial structure | Monthly retainer with FTE assumptions | Discovery, Build, Run priced independently |
| Control surface | Manual audit cycles | Versioned artefacts, signed audit log, named owners per control |
| Throughput-per-FTE | 1.0× (baseline) | Net positive |
| Unit economics | Unchanged from baseline | 60-80% lower on routine cases |
| Termination clause | Multi-quarter notice; documentation gaps | Month-to-month Run; handover plan in Build SoW |
Traditional process automation projects cost $80-200k+ with 6-12 month payback; AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting.
Engagement scope & pricing
The commercial envelope is set at Discovery and held through Build. Run is optional and month-to-month — the exit path is part of the engagement, not a separate negotiation.
Governed engagement
Fixed prices per phase, no multi-quarter commitments, exit possible at every phase boundary.
Phase 1 · Discovery
$8k
2-3 week sprint
Phase 2 · Build
$30k–$40k
8-12 weeks
Phase 3 · Run
$4k–$6k / mo
optional, quarterly attestations available
~$52k–$90k typical year 1 (~80% take the run option, regulated workflows need ongoing controls)
Controls, audit logs, reviewer queues, versioned prompts, and quarterly risk attestations.
Discovery contains its own value (the workflow map, the baseline, the SoW). You can stop after Discovery and still own the artefacts. If you proceed, Build is fixed-scope and fixed-price.
The 4-phase delivery model
Phase 1 · Weeks 1–2
Discovery
Discovery is short, intense, and decision-producing. By end of week 2, you have the workflow map, the baseline, the SoW, and the risk register. No code yet — the next phase is calibrated against this evidence.
Phase 2 · Weeks 2–4
Design
Design phase is where the irreversible architectural choices are made: layer boundaries, substitution interfaces, governance posture, evaluation methodology. We invest disproportionately here because corrections in Build are 10× more expensive.
Phase 3 · Weeks 4–8
Build
Vertical-slice delivery against the labelled test set. Each slice ships to production, gated by eval criteria. By end of Build, the workflow is operating on real traffic with the calibration discipline established.
Phase 4 · Weeks 8+
Run
Run is where AI accuracy stops being a one-time evaluation result and becomes a sustained operating metric. We run the weekly cadence; your team takes ownership progressively over the first quarter.
Interactive ROI calculator
Estimate your AI-native ROI for quality assurance
Reference inputs below are typical for pharmaceuticals teams in the risk compliance cluster. Adjust them to match your situation.
Projected
Current monthly cost
$57,000
AI-native monthly cost
$20,070
Annual savings
$443,160
65% cost reduction · ~656 operator-hours freed / month
Governance and risk controls
The cost of getting governance wrong in pharmaceuticals is asymmetric: a single failure on medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails can cost more than the entire AI engagement saved. We treat governance as the first design constraint, not the last documentation pass. The architecture decisions in Build are made against the risk map captured in Discovery, not retrofitted at the end.
How we report ROI
We commit to a baseline-vs-actuals report every week of Run. The baseline is captured in Discovery (current defect rate, review cycle time, rework, and audit findings, current medical response time, content approval cycle time, field productivity, and safety case throughput); the actuals come from the workflow itself. ROI is not modelled — it is measured and signed off by a named owner on your team. The first 30-day report is the gate to expansion.
Selected portfolio
Real builds — quality assurance in pharmaceuticals and adjacent sectors
Below are engagements drawn from our active portfolio where the workflow rhymed with quality assurance in pharmaceuticals or in adjacent contexts. Scope and stack are accurate; client identities are withheld under engagement NDAs.
Q3 2025
Radiology workflow application — case handling and reporting
Medical imaging operator · Europe
Application supporting radiology workflow: case intake, structured reporting, document handling, and quality-assurance loop. Designed for regulated medical-imaging context with audit trail and role-based access.
- Web app + secure storage
- Structured reporting
- Audit-trail compliance
Q2 2026
Authenticated remote voting platform — AGM resolutions, audit trail, EN/AR bilingual
Mid-market property operator · GCC region
Purpose-built e-voting system: per-unit cryptographic authentication, AGM resolution console for admins, real-time tally, full per-vote audit log. Federated identity with the OA management platform so owners use one login. Bilingual EN/AR from day one.
- Next.js + tRPC
- Per-unit auth + audit trail
- Bilingual EN/AR (next-intl)
Q2 2026
Internal staff portal — multi-association operations in role-based dashboards
Mid-market property operator · GCC region
Role-scoped portal for property managers, accountants, and maintenance staff. Reuses the OA data model from the management SaaS (zero duplication), adds multi-association switching, maintenance ticket lifecycle, financial reporting, and document storage tied to each association workspace.
- Next.js + tRPC
- NextAuth role-based access
- Drizzle ORM shared schema
Client identities withheld under engagement NDAs. Sector, geography, and scope are accurate. Full case studies on request.
Common pitfall & mitigation
The failure mode we see most often on AI-native quality assurance engagements in pharmaceuticals contexts.
Hallucinated citations under deadline pressure
AI fabricates a regulation reference during a busy week, reviewer misses it
Citation grounding required (no citation = refuse); periodic adversarial test set with fake-citation triggers
Audit-grade delivery for a regulated workflow
Third-party risk management for AI components in pharmaceuticals is a growing concern that most workflows handle poorly. quality assurance engagements typically depend on a model provider, a retrieval store, a vector database, sometimes a fine-tuning service. Each is a vendor in your risk register. We map them all during Build, document substitution paths for each, and demonstrate substitutability in the eval harness — so when one vendor changes pricing, terms, or availability, the workflow can move without a re-architecture.
What actually happens in the first month
If you have ever shipped a non-trivial production system you know the first 30 days are make-or-break. For quality assurance in pharmaceuticals, the make-or-break decisions are: what does the labelled test set look like, what is in scope for the integration against CRM, where does the automation boundary sit, and how is the reviewer queue UX going to feel to your operator team. We answer all four in the first two weeks.
Labelled test set: 200 cases minimum by end of week 2, signed off by the engagement sponsor, covering routine, exceptional, ambiguous, and adversarial. Integration scope: documented and bounded by end of week 1, with the data-access plan reviewed by your engineering team. Automation boundary: drawn deliberately in week 2 — full automation lane, drafted-with-review lane, reserved-to-human lane — with confidence thresholds calibrated against the test set. Reviewer UX: prototyped in week 2 with two of your senior operators in the loop, iterated through week 3.
From day 30, the Build sprint shifts to widening the envelope. The decisions made in the first month are the ones that shape the next 12 months of operating the workflow — which is why we resist the temptation to skip ahead to the model layer before the test set and the reviewer UX have been earned.
For pharmaceuticals engagements on quality assurance, the first 30 days are not about building features — they are about producing the labelled test set that will govern every subsequent decision. The test set is the most valuable artefact of the engagement, because it is what makes "did this change make the workflow better?" a measurable question instead of an opinion.
We spend week 1 on test-set capture. The operator team picks 200-400 representative cases spanning routine, exceptional, ambiguous, and adversarial. Each case has the expected outcome, the expected reasoning, and the source citations a reviewer would want to see. The test set is reviewed for coverage gaps, signed off by the engagement sponsor, and version-controlled alongside the prompts.
From week 2, every prompt change, retrieval-index update, and threshold calibration is gated by the eval harness running against this test set. Improvements that beat the incumbent across enough metric slices get promoted; changes that look impressive on one slice but regress on another are flagged for review. By the end of Build, the test set has grown to 600-1000 cases, the workflow has been through 15-25 eval cycles, and pharmaceuticals leadership has empirical evidence that the system performs on their data, not on a vendor's demo.
This is the practice most pharmaceuticals AI projects skip because it looks like overhead in the first three weeks. It is the practice that determines whether the workflow survives the third quarter of Run, which is why we treat it as the foundation of Build rather than an afterthought.
Recent build that maps to this engagement
The recent build in our portfolio that maps cleanest to quality assurance in pharmaceuticals is summarised below. Identity withheld under engagement NDA; sector and stack are accurate.
Radiology workflow application — case handling and reporting. Application supporting radiology workflow: case intake, structured reporting, document handling, and quality-assurance loop. Designed for regulated medical-imaging context with audit trail and role-based access. (Medical imaging operator · Europe, Q3 2025.)
The reason that engagement is a useful reference is not the surface match — it is the underlying decision structure. The same questions show up on quality assurance for pharmaceuticals: where to draw the automation boundary, how to calibrate confidence thresholds against the labelled test set, what to put in the reviewer UI, how to instrument drift. The answers transfer; the implementation specifics adapt to your stack.
For US buyers
US compliance scaffolding for quality assurance in pharmaceuticals (FDA 21 CFR Part 11, HIPAA, NIST AI RMF)
Pharmaceuticals engagements touching US clients on quality assurance ship with the regulatory scaffolding your procurement, compliance, and legal teams expect. The framework that matters most for pharmaceuticals is Electronic Records and Electronic Signatures (FDA 21 CFR Part 11) — addressed below alongside the adjacent frames we encounter.
FDA 21 CFR Part 11
Electronic Records and Electronic Signatures
Authority: U.S. Food and Drug Administration
- Scope
- Validation of electronic records in GxP environments, audit trails, electronic signatures, system access controls.
- How we ship inside it
- Pharma and medical-device engagements include 21 CFR Part 11 system validation documentation: design qualification (DQ), installation qualification (IQ), operational qualification (OQ), performance qualification (PQ). Audit trails are tamper-evident and signature-bound.
HIPAA
Health Insurance Portability and Accountability Act
Authority: U.S. Department of Health and Human Services / OCR
- Scope
- Protected Health Information (PHI) handling, security safeguards, breach notification, business associate accountability.
- How we ship inside it
- We sign a Business Associate Agreement (BAA) on healthcare engagements that touch PHI. The architecture supports BAA-covered model providers (Anthropic BAA, Azure OpenAI BAA, AWS Bedrock BAA). Audit log retention defaults to 6 years (HIPAA minimum). PHI handling follows minimum-necessary principle at the prompt and retrieval layers.
NIST AI RMF
NIST AI Risk Management Framework (AI 100-1)
Authority: U.S. National Institute of Standards and Technology
- Scope
- Voluntary framework: Govern, Map, Measure, Manage functions for AI system risk.
- How we ship inside it
- Every engagement maps to NIST AI RMF during Discovery. The control map produced becomes the artefact your internal audit and security teams use to defend the workflow.
For US companies
Start a US-friendly engagement
Discovery from $8,500–$12,000, Build from $35,000–$75,000, optional Run from $5k/mo. Fixed-price, milestone-billed, you own every artefact. Send a short brief and we reply within 5 business days. 11am–4pm ET overlap for live syncs.
USD pricing
Discovery $8,500–$12,000 · Build $35,000–$75,000
US-style commercial
MSA / SOW / mutual NDA standard. DPA with SCCs included.
Limited capacity
We onboard 3–5 new clients per quarter to protect delivery quality.
Build internally or work with us
The strongest pattern we see in pharmaceuticals is blended: we design and launch the first production workflow, your internal team owns data access, security review, and stakeholder alignment. Over 6-12 months, your team takes over Run while we move to the next workflow. The exit plan is part of the Statement of Work.
What to ask us before signing
- Ask for the labelled test set methodology — how many cases, what the coverage gaps are, who signs them off.
- Ask where the prompt library and retrieval index will live (your cloud or ours) and what happens to them at the end of Run.
- Ask how we calibrate confidence thresholds and how often they are revisited against the pharmaceuticals reality.
- Ask for the audit log architecture — what is logged, how long it is retained, who can query it.
- Ask how a senior operator on your team becomes the first reviewer and what onboarding we ship to support them.
Recommended first project
The first project we recommend for pharmaceuticals on quality assurance is rarely the one leadership names in the initial conversation. The named project is usually the most politically visible — which is also the riskiest place to ship a first AI-native workflow. We typically recommend the adjacent subflow with the cleanest baseline, the smallest blast radius, and the most repetitive operator work. That first project produces three artefacts that the visible project needs: a labelled test set the operator team has signed off on, a reference architecture against CRM, and a credibility track record with the internal stakeholders who will be asked to support the second engagement. By the time we propose the second workflow — the visible one — the organisational gravity is on our side.
Frequently asked questions
How do you automate quality assurance in pharmaceuticals with AI?+
For pharmaceuticals, the build is biased toward operational durability over demo-grade polish. We instrument every case end-to-end (intake → context → action → review), gate every prompt change behind an evaluation harness, and integrate against CRM + medical information systems. The workflow goes to production in 6-10 weeks and operates against defect rate, review cycle time, rework, and audit findings.
What does it cost to automate quality assurance for pharmaceuticals teams?+
Phased pricing — you commit to one phase at a time. Discovery is $8k for 2-3 week sprint. Build, scoped from Discovery, runs $30k–$40k over 8-12 weeks. Run is opt-in at $4k–$6k / mo per optional, quarterly attestations available. ~$52k–$90k typical year 1 (~80% take the run option, regulated workflows need ongoing controls)
What is the best AI agent for quality assurance in pharmaceuticals?+
The model is rarely the most consequential choice on quality assurance in pharmaceuticals. What matters more: the retrieval shape against your approved sources, the confidence-threshold calibration against the labelled test set, the reviewer queue UX, and the audit log architecture. We benchmark frontier models (Claude, GPT-4-class, Gemini) against your data and select for the accuracy/cost/latency profile that fits your operational reality — not a generic leaderboard.
How long does it take to deploy AI quality assurance for pharmaceuticals?+
Production traffic on quality assurance for pharmaceuticals typically starts at week 6-8 of Build, after the labelled test set, the eval harness, the reviewer queue, and the audit log are all in place. The first quarter of Run is paired operation — your team takes the dashboard, we stay on the architecture decisions. By the end of the first Run quarter, your team is operating the workflow with the cadence we ship as part of Build.
What do we own, and what do you own?+
The ownership boundary is documented in the Build statement of work. Our side: workflow architecture, prompt library, retrieval shape, evaluation harness, reviewer-queue design, audit log architecture, weekly operating cadence. Your side: data access, source curation by your subject-matter experts, policy interpretation, exception approval, final commercial decisions. Every artefact is yours at the end of Run.
How do you handle risk and audit for AI quality assurance in pharmaceuticals?+
Every output is grounded in approved sources, every prompt is versioned, and every reviewer action is logged. We provide a control map covering medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails, plus quarterly attestations on request.
Do you train models on our data?+
No. We do not train any model on client data. Anthropic Zero-Data-Retention is enabled by default; OpenAI default-no-training is honoured. Prompts, retrieval indexes, audit logs, and integration data live in your cloud account under your IAM. At engagement end, every artefact transfers to your repository.
What if we want to exit the engagement?+
Discovery and Build are fixed-scope, so there is no mid-engagement exit cost. Run is month-to-month with 30-day notice. Every artefact (prompts, eval harness, integration code, dashboards, runbooks) is in your repository throughout the engagement, not behind our SaaS. There is no lock-in.
What does success look like 90 days after Build closes?+
defect rate, review cycle time, rework, and audit findings measurably improved against the Discovery baseline. Your team is operating the workflow with the cadence we shipped during Build. The audit log is queryable. The reviewer queue is calibrated. The next workflow scope is informed by real production evidence rather than initial assumptions.
What support is included after the engagement ends?+
Optional Run retainer covers weekly cadence, prompt refresh, retrieval index updates, and reviewer-queue calibration. Architecture-level questions and breaking-change support are billed hourly outside of Run. Most engagements transition Run in-house at month 6-12; we stay available for architecture decisions for 12 months at no extra charge.
How does this integrate with CRM and our existing stack?+
Discovery scopes the integration footprint explicitly. We integrate at the API layer; no replatforming required. The Build statement of work names exactly which systems are connected, which data flows are bidirectional, and what authentication patterns we use (SSO, service accounts, OAuth scopes). The integration code lives in your repository.
What does your team look like during an engagement?+
Discovery: 1 senior delivery lead + 1 PM, ~30 hours/week. Build: 1 senior delivery lead + 2-3 senior AI engineers, ~50-80 hours/week across the team. Run: 1 delivery owner + 1 engineer on weekly cadence. We do not use offshore staff augmentation. Every engineer touching your engagement is senior-level.
Sources we reference
The following sources inform the architecture, governance, and benchmarks we apply on pharmaceuticals engagements. Cited here so you can verify and dig deeper.
- FDA Artificial Intelligence
- Responsible Scaling Policy — Anthropic
- AI Index Report — Stanford HAI
- Model Risk Management Handbook — Federal Reserve (SR 11-7)
- Principles for the Sound Management of AI Risks — BIS Financial Stability Institute
- Google Search Central: helpful, reliable, people-first content
- Google Search Central: URL structure best practices
Concepts on this page:
AI governance·NIST AI RMF·Audit log·Grounding·Guardrails·Model cardFull glossary →High-intent reads
Start the engagement
Start a Pharmaceuticals engagement
Tell us about your workflow, the systems involved, and the KPI you want to move. We'll send a scoped statement of work within 5 business days.